BioSpace News Archive

RVL Pharmaceuticals plc, a specialty pharmaceutical company focused on the commercialization of UPNEEQ®, 0.1%, announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open.

NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m.

Protalix BioTherapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Aptose Biosciences Inc. today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets 2023 Global Healthcare Conference on May 17, 2023.

C4 Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2023, as well as recent business highlights.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 1 clinical trial with TNX-1500 (anti-CD40L monoclonal antibody [mAb]).

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20, in Los Angeles.

Stoke Therapeutics, Inc. today reported financial results for the first quarter of 2023 and provided business updates including those related to STK-001, the company’s proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential new medicine to address the genetic cause of Dravet syndrome.

Silence Therapeutics plc today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program.

908 Devices Inc announced the release of a data analysis tool that provides a quick and effortless way to analyze and visualize the wealth of data generated by the REBEL at-line cell culture media analyzer.